Evidence Table 129. KQ3—Dichotomous—Fasting blood glucose

| **Author Year****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Napoli199852Parallel | Data imputed- there were no differences between baseline and post treatment values. | Unclear | Pravastatin (20-40) | Vitamin E |  | 0 | No Treatment |  | 0 |  | No differences in routine laboratory tests or adverse events were registered during the study in particular there were no differences between the values recorded in each individual after treatment compared to baseline values, and no differences between the treatment groups. | Medium |
| Reyes198459Parallel | NR | Mixed: Low and/or Moderate | Hydrochlorothiazide (50) | Magnesium | 13 | 0 | Placebo | 8 | 0 |  |  | Medium |